BVS · Bioventus Inc.
Market Cap
$1.09B
Shares
84.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.98
Open$13.28
Day$12.92–13.35
52W close$6.51–15.26
Avg vol 30d720K
Short int2.6M · 3.1% float · 4.7d
Short vol63%
Last earningsAug 5, 2026
DataFeb 2021–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 7 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$581.85M
Trailing 12 months
Net income (TTM)
$54.46M
Trailing 12 months
Revenue growth YoY
+3.8%
Year over year
Operating margin
10.0%
Trailing 12 months
P / E (TTM)
16.9
Trailing earnings · reciprocal yield 5.9%
FCF yield
8.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$219.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.4%
Year over year · more shares
Price change (1Y)
+78.3%
Trailing year
Short interest
3.1%
Latest settlement · 4.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Bioventus reported Q2 revenue of $153.2 million (up 4%) driven by double-digit Pain Treatments growth, reaffirmed full-year 2026 guidance, made a $20 million discretionary debt prepayment, and initiated a review of strategic alternatives following an unsolicited acquisition proposal.
Bullish
- + Made a $20.0 million discretionary principal prepayment on term loan, with debt pay down of $46 million YTD and leverage below 2x
- + Board initiated review of strategic alternatives following unsolicited acquisition proposal and multiple expressions of interest
- + PRP and PNS businesses showed accelerated capital placements, new customer wins, and positive market feedback
Bearish
- − Company took proactive channel actions in BGS during Q2 that had a temporary impact on the business
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
−1%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+50%
trailing
YTD return
+74%
this year
Relative strength
+32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.07% of float · ▲ +10.6% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−1%
Y/Y
Gross margin
68%
expanding
EPS growth
+159%
Y/Y
Free cash flow
$72.1M
Valuation
P/E 16.9
below peers
Balance sheet
$242.7M
net debt
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Adjusted EPS
· twelve months ending December 31, 2026
Initiated
$0.75 – $0.79
Cash from Operations
· twelve months ending December 31, 2026
Initiated
$84M – $89M
Prior guidance
period ended
· from the 8-K filed Aug 6, 2024
Non-GAAP EPS*
· full-year 2024
$0.36 – $0.42
Guided vs delivered
· last 1 settled
2021 revenue
2021
guided $425M – $430M
$430.9M
Beat +0.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $10 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.07% of float · ▲ +10.6% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $13 · 74%
Range high $15
vs 200-day avg +32%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BVS
this stock
Bioventus Inc.
|
$1.09B | +74.5% | -0.9% | 16.9 | 3.1% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BVS | -9.6% | -6.6% | +50.2% | -4.9% | +74.5% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -8.5% | -4.8% | +32.4% | -4.6% | +62.4% |
Key facts
CIK
1665988
CUSIP
09075A108
13F (30d)
54 filings
54 filers
Visit website
Investor relations